The approved roles of PARPis in ovarian cancer fall into two main approaches: treatment of recurrent disease (the PARP inhibitor is used to shrink the tumor), and maintenance after response to platinum-based chemotherapy. The gene discussed is PARP1; the disease is ovarian cancer.